EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Challenges and Innovation for Diagnosing and Treatment of Secondary Progressive Multiple Sclerosis

Ekdanai Uawithya iD, Joshua S Mytych iD, Ismail Muwenda iD, Megan Reidy, Meerah Khan, Yang Mao-Draayer

International Journal of Molecular Sciences · 19.05.2026 · 27 (10) · 4558

DOI: 10.3390/ijms27104558 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.05.2026. Verfasst von Ekdanai Uawithya und 5 weiteren Autor:innen. Beteiligte Einrichtung: Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104, USA. Hauptthemen laut MEDLINE: Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting. Die Arbeit nennt 197 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The transition from relapsing–remitting multiple sclerosis (RRMS) to secondary-progressive multiple sclerosis (SPMS) represents an ambiguous transition period characterized by diagnostic delays and a shifting therapeutic window. While inflammatory relapses are well-managed, the underlying neurodegeneration often remains undetected until substantial disability has accrued. This review evaluated the shift from traditional metrics, such as the Expanded Disability Status Scale (EDSS), toward more sensitive, multimodal monitoring strategies. We described characteristic MRI findings in SPMS and addressed the impact of comorbidities that frequently confound the diagnosis of disease transition. Furthermore, we evaluated the predictive potential of emerging fluid biomarkers and gut microbial signatures in identifying the early RRMS-to-SPMS transition. Finally, we described the current therapeutic landscape and emerging immunomodulatory interventions. Diagnosing SPMS remains a clinical challenge due to comorbidities and the lack of a singular definitive marker. Moving toward high-sensitivity imaging and molecular biomarkers is essential for the early initiation of treatments and improved patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple Sclerosis, Chronic ProgressiveMultiple Sclerosis, Relapsing-RemittingHumansBiomarkersMagnetic Resonance ImagingDisease Progression

Stichwörter der Autor:innen

multiple sclerosisprogressivetreatment

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104, USA.

ORCID-Profile: Ekdanai Uawithya, Joshua S Mytych, Ismail Muwenda

Zitieren

APA

Uawithya, E., Mytych, J. S., Muwenda, I., Reidy, M., Khan, M., & Mao-Draayer, Y. (2026). Challenges and Innovation for Diagnosing and Treatment of Secondary Progressive Multiple Sclerosis. International Journal of Molecular Sciences, 27(10), 4558. https://doi.org/10.3390/ijms27104558

Vancouver

Uawithya E, Mytych JS, Muwenda I, Reidy M, Khan M, Mao-Draayer Y. Challenges and Innovation for Diagnosing and Treatment of Secondary Progressive Multiple Sclerosis. International Journal of Molecular Sciences. 2026;27(10):4558. doi:10.3390/ijms27104558

BibTeX
@article{Uawithya2026,
  author = {Uawithya, Ekdanai and Mytych, Joshua S and Muwenda, Ismail and Reidy, Megan and Khan, Meerah and Mao-Draayer, Yang},
  title = {Challenges and Innovation for Diagnosing and Treatment of Secondary Progressive Multiple Sclerosis},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {10},
  pages = {4558},
  doi = {10.3390/ijms27104558}
}
Kostenlos starten →